CA2529436A1 - Derives de pyrazolidinedione - Google Patents

Derives de pyrazolidinedione Download PDF

Info

Publication number
CA2529436A1
CA2529436A1 CA002529436A CA2529436A CA2529436A1 CA 2529436 A1 CA2529436 A1 CA 2529436A1 CA 002529436 A CA002529436 A CA 002529436A CA 2529436 A CA2529436 A CA 2529436A CA 2529436 A1 CA2529436 A1 CA 2529436A1
Authority
CA
Canada
Prior art keywords
phenyl
propoxy
dione
pyrazolidine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002529436A
Other languages
English (en)
Inventor
Olivier Houille
Heinz Fretz
Kurt Hilpert
Markus Riederer
Thomas Giller
Olivier Valdenaire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2529436A1 publication Critical patent/CA2529436A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/62—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by hydrogenation of carbon-to-carbon double or triple bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/542—Alkylated benzaldehydes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/548—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/56—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups
    • C07C47/565—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms
    • C07D231/30—Two oxygen or sulfur atoms attached in positions 3 and 5
    • C07D231/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des dérivés de pyrazolidinédione de formule générale (I), dans laquelle R¿1? désigne un hydrogène, un alkyle éventuellement substitué, un cycloalkyle, un aryle, un arylalkyle, un hétéroaryle, un hétéroarylalkyle ou un alkanoyle; et R¿2? représente un aryle ou un hétéroaryle; des tautomères de ceux-ci; des isomères géométriques de ceux-ci et des tautomères de ces isomères géométriques, notamment des mélanges de composés individuels de formule (I), ou des tautomères de ceux-ci, et des isomères géométriques de ceux-ci ou des tautomères de ceux-ci, des sels d'ajout acides acceptables sur le plan pharmaceutique des composés qui sont basiques; des sels acceptables sur le plan pharmaceutique de composés renfermant des groupes acides avec des bases; des esters acceptables sur le plan pharmaceutique des composés renfermant des groupes hydroxy ou carboxy; des promédicaments de composés dans lesquels un groupe formant un promédicament est présent; ainsi que des hydrates ou solvates de ceux-ci; lesdits dérivés sont actifs comme antagonistes du récepteur de l'adénosine diphosphate des plaquettes et peuvent être utilisés pour la prévention et/ou le traitement de maladies vasculaires périphériques, vasculaires viscérales, hépatiques et rénales, cardio-vasculaires et cérébro-vasculaires ou d'états associés à l'agrégation plaquettaire, notamment la thrombose et, respectivement, pour la fabrication des médicaments correspondants. Quelques composés, mais pas tous, de la formule (I) susmentionnée sont nouveaux.
CA002529436A 2003-06-24 2004-06-16 Derives de pyrazolidinedione Abandoned CA2529436A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP03/006616 2003-06-24
PCT/EP2003/006616 WO2005002574A1 (fr) 2003-06-24 2003-06-24 Derives de pyrazolidinedione et leur utilisation en tant qu'inhibiteurs de l'agregation des plaquettes
PCT/EP2004/006471 WO2005000281A2 (fr) 2003-06-24 2004-06-16 Derives de pyrazolidinedione

Publications (1)

Publication Number Publication Date
CA2529436A1 true CA2529436A1 (fr) 2005-01-16

Family

ID=33547562

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002529436A Abandoned CA2529436A1 (fr) 2003-06-24 2004-06-16 Derives de pyrazolidinedione

Country Status (6)

Country Link
EP (1) EP1638540A2 (fr)
JP (1) JP2007506661A (fr)
CN (1) CN1812782A (fr)
AU (1) AU2003249865A1 (fr)
CA (1) CA2529436A1 (fr)
WO (2) WO2005002574A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070276011A1 (en) * 2003-09-11 2007-11-29 Susumu Muto Plasminogen Activator Inhibitor-1 Inhibitor
JPWO2007020935A1 (ja) * 2005-08-17 2009-02-26 小野薬品工業株式会社 Ｐ２ｙ１２受容体および／またはｐ２ｙ１４受容体ブロッカーを含有してなる疼痛治療剤
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
JP5560202B2 (ja) 2007-12-26 2014-07-23 サノフイ Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
WO2009080226A2 (fr) 2007-12-26 2009-07-02 Sanofis-Aventis Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12
JP6016788B2 (ja) * 2011-05-16 2016-10-26 国立大学法人九州大学 ＤＯＣＫ−Ａサブファミリー分子によるＲａｃ活性化を制御する低分子化合物及びその用途
WO2017038650A1 (fr) * 2015-08-28 2017-03-09 積水メディカル株式会社 Composé benzyle
US10730830B2 (en) 2016-01-29 2020-08-04 Ono Pharmaceutical Co., Ltd. Tetrahydronaphthalene derivative
TWI765002B (zh) * 2017-03-15 2022-05-21 瑞士商愛杜西亞製藥有限公司 受體拮抗劑之皮下投藥
US11584710B2 (en) 2017-07-31 2023-02-21 Horitzonts Tecnologics Hungary Korlátolt Felelosségu Társaság Compounds for treating infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2012634A1 (fr) * 1990-03-20 1991-09-20 Hassan Salari Tyrphostines pour le traitement des allergies et des affections inflammatoires et cardiovasculaires
CA2380644A1 (fr) * 1999-07-30 2001-02-08 Basf Aktiengesellschaft 2-pyrazolin-5-ones
IL159354A0 (en) * 2001-06-18 2004-06-01 Applied Research Systems Use of alklidene pyrazolidinedione derivatives in polycystic ovary syndrome, some novel such derivatives, their preparation and pharmaceutical compositions containing them
WO2003002569A1 (fr) * 2001-06-29 2003-01-09 Novo Nordisk A/S Procede permettant d'inhiber ptp1b et / ou ptp de lymphocyte t et / ou d'autres ptpases a reste asp en position 48
AU2003213673A1 (en) * 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof

Also Published As

Publication number Publication date
WO2005000281A3 (fr) 2005-04-14
JP2007506661A (ja) 2007-03-22
CN1812782A (zh) 2006-08-02
EP1638540A2 (fr) 2006-03-29
WO2005002574A1 (fr) 2005-01-13
WO2005000281A2 (fr) 2005-01-06
AU2003249865A1 (en) 2005-01-21

Similar Documents

Publication Publication Date Title
JP7061161B2 (ja) 核内輸送調節因子およびその使用
US6387942B2 (en) Method of treating disorders related to protease-activated receptors-induced cell activation
CN104822672A (zh) 治疗性化合物和组合物以及其作为pkm2调节剂的用途
KR102562576B1 (ko) 유기 화합물
CA2641345A1 (fr) Derives d'indazole pour le traitement de la maladie d'alzheimer
TW509682B (en) Phthalazine derivatives phosphodiesterase 4 inhibitors
CA2560098A1 (fr) Derive de 2-aminoquinazoline
CA2529436A1 (fr) Derives de pyrazolidinedione
JP2506541B2 (ja) イミダゾピリジンｐａｆ／ｈ▲下１▼拮抗薬
JP5063348B2 (ja) ２−スルファニル−ベンゾイミダゾール−１−イル−酢酸誘導体
WO2012009137A1 (fr) Modulateurs de crth2
US20070037846A1 (en) Pyrazolidinedione derivatives
TW201130810A (en) CRTH2 modulators
JPS62108814A (ja) 過酸化脂質生成抑制剤
KR20040072733A (ko) 칼슘채널 차단제로서의 1,4-디하이드로피리딘 및 피리딘화합물
CA2547791A1 (fr) Composes therapeutiques
JP2022505625A (ja) 新規化合物
WO2024169781A1 (fr) Dérivé de pyrimidinone et son application pharmaceutique
CN116041300B (zh) 一种2,2-二甲基苯并吡喃类衍生物及其制备方法和应用
JP4903941B2 (ja) 縮合ピラゾール化合物
JPH07501532A (ja) 抗喘息性，および気管支抗炎症作用を有する［３Ｈ，７Ｈ］チアゾール［３，４‐ａ］ピリジン

Legal Events

Date Code Title Description
FZDE Dead